Executives to Lead Company’s Technology and Finance Teams with a Focus on Service Delivery and Driving Global Growth

MORRISVILLE, N.C. (Business Wire) January 20, 2010 — Clinipace Worldwide, a global technology-driven clinical research organization (CRO), announced today the addition of Bud Owen, chief financial officer, and Daryl Porter, chief technology officer, to its growing team. Both Owen and Porter bring substantial experience helping firms grow through technology integration and M&A strategies.

As CFO, Owen leads the accounting, treasury, and tax group and is a key member of the mergers and acquisitions team for the company. He initially joined Clinipace as an advisor during the recent acquisition of Worldwide Clinical Research. Prior to joining Clinipace, Owen served as chief financial officer at a number of large and small companies in the software, web services, and manufacturing industries, including MediaSpan Group, Reichhold Chemicals, and Tables Surfaces, a company he co-founded. As a veteran senior finance executive with extensive merger and acquisition expertise, he has been either principal or advisor in over 30 M&A transactions with a total value of $1 billion.

In his new role as CTO, Porter leads the service engineering, product engineering, and cloud computing infrastructure teams. Prior to Clinipace Worldwide, Porter spent 18 years at Oracle Corporation and held several executive-level positions in both enterprise product development and enterprise support services. In his most recent role as vice president in Advanced Support Services, he was responsible, in part, for streamlining software lifecycle services for global, distributed teams of over 10,000 professionals in five countries. Additionally, he was an integral member of the Oracle M&A technical team tasked with conducting due diligence on Oracle’s acquisitions of Siebel and PeopleSoft.

“As a rapidly growing global CRO business backed by triple digit growth over the past 12 months, we look forward to leveraging Bud and Daryl’s industry knowledge and expertise to help our company implement our acquisition and technology strategies,” said Jeff Williams, Clinipace Worldwide CEO. “Their leadership and experience are critical to our success as we continue to expand globally and seek to provide our customers with the highest quality technology-driven clinical research services in the industry.”

About Clinipace Worldwide

Clinipace Worldwide is a global technology-driven clinical research organization (CRO) specializing in fully-integrated clinical research services for growth-oriented and mid-tier biopharmaceutical and medical device firms. Its team of therapeutic experts brings extensive investigator site selection, patient recruitment, clinical operations, data management, EDC software, biostatistics, and regulatory knowledge and insight into successful clinical development through proactive clinical trial management. With specific expertise in oncology, among other therapeutic areas, Clinipace Worldwide has managed over 90 contract research projects conducted at almost 3,000 sites with 100,000 patients. Clinipace Worldwide is headquartered in Research Triangle Park, NC with additional domestic operations in Overland Park, KS, and South American operations based in Brazil, Argentina, and Peru.